在阿尔茨海默病患者和健康个体尿液中检测β淀粉样蛋白。
Detection of amyloid beta protein in the urine of Alzheimer's disease patients and healthy individuals.
作者信息
Takata Manabu, Nakashima Manabu, Takehara Taro, Baba Hideyo, Machida Kazuyuki, Akitake Yoshiharu, Ono Kazuhiko, Hosokawa Masato, Takahashi Mitsuo
机构信息
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
出版信息
Neurosci Lett. 2008 Apr 18;435(2):126-30. doi: 10.1016/j.neulet.2008.02.019. Epub 2008 Feb 16.
To seek for a new valid biomarker using non-invasive specimens for the diagnosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI), we carried out the detection of amyloid beta (Abeta) protein in urine. Ten-millilitre urine samples were first sedimented with trichloroacetic acid, and the pellets were resuspended for further analysis by Western blotting with anti-Abeta antibody. The detection sensitivity of the method was 40pg/ml. Rates of subjects positive for monomeric Abeta according to their clinical dementia rating (CDR) were 11.1% for CDR 0, 62.5% for CDR 0.5, 83.3% for CDR 1, 54.5% for CDR 2 and 0% for CDR 3. A single Abeta band relative to the CDR score reflects an alteration in the production, solubility and clearance of Abeta in the brain. Thus, the method could be used as both a diagnostic and monitoring tool in assessing AD and MCI patients during disease-modifying therapies.
为了寻找一种新的有效生物标志物，用于使用非侵入性标本诊断阿尔茨海默病（AD）和轻度认知障碍（MCI），我们对尿液中的淀粉样β蛋白（Aβ）进行了检测。首先用三氯乙酸沉淀10毫升尿液样本，将沉淀重悬后，用抗Aβ抗体通过蛋白质印迹法进行进一步分析。该方法的检测灵敏度为40pg/ml。根据临床痴呆评定量表（CDR），单体Aβ呈阳性的受试者比例为：CDR 0时为11.1%，CDR 0.5时为62.5%，CDR 1时为83.3%，CDR 2时为54.5%，CDR 3时为0%。相对于CDR评分的单一Aβ条带反映了大脑中Aβ的产生、溶解度和清除率的改变。因此，该方法可作为一种诊断和监测工具，用于在疾病修饰治疗期间评估AD和MCI患者。
Zotero 插件